Janux Therapeutics (JANX) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 11, 2026, to be held virtually for stockholders of record as of April 17, 2026.

• Proxy materials, including the notice, proxy statement, and annual report, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of two Class II director nominees, Natasha Hernday and Eric Dobmeier, for three-year terms ending at the 2029 annual meeting.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Advisory vote to approve the compensation of named executive officers as disclosed in the proxy statement.

• Provision to conduct any other business properly brought before the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all three main proposals presented at the annual meeting.